Phase III-Ready Anticoagulant Awaits Cash from Regado IPO
By Randy Osborne
Wednesday, May 1, 2013
The possibility of an initial public offering (IPO) noted in December, when Regado Biosciences Inc. collected $51 million in a Series E financing intended to help fund Phase III trials moved closer to reality, as the firm filed a registration statement to trade on Wall Street.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.